Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDMeD: Empagliflozin for DMD-associated Cardiomyopathy
NCT06643442Phase 2Not yet recruiting
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM)
Beyond the preview
Go deeper on NCT06643442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643442.